Suppr超能文献

EORTC QLQ-CIPN20 用于评估接受神经毒性化疗的患者周围神经病变恶化的最小临床重要差异。

Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.

机构信息

Department of Pharmacy, National University of Singapore, Blk S4A Level 3, 18 Science Drive 4, Singapore, 117543, Singapore.

Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

出版信息

Support Care Cancer. 2019 Dec;27(12):4753-4762. doi: 10.1007/s00520-019-04771-8. Epub 2019 Apr 10.

Abstract

CONTEXT/OBJECTIVES: This is the first study to determine the minimal clinically important difference (MCID) of the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (EORTC QLQ-CIPN20), a validated instrument designed to elicit cancer patients' experience of symptoms and functional limitations related to chemotherapy-induced peripheral neuropathy.

METHODS

Cancer patients receiving neurotoxic chemotherapy completed EORTC QLQ-CIPN20 and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity [FACT/GOG-NTX] at baseline, second cycle of chemotherapy (T2, n = 287), and 12 months after chemotherapy (T3, n = 191). Anchor-based approach used the validated FACT/GOG-NTX neurotoxicity (Ntx) subscale to identify optimal MCID cutoff for deterioration. Distribution-based approach used one-third standard deviation (SD), half SD, and one standard error of measurement of the total EORTC QLQ-CIPN20 score.

RESULTS

There was a moderate correlation between the change scores of the Ntx subscale and sensory and motor subscales of QLQ-CIPN20 (T2: r = - 0.722, p < 0.001 and r = - 0.518, p < 0.001, respectively; T3: r = - 0.699; p < 0.001 and r = - 0.523, p < 0.001, respectively). The correlation between the change scores of the Ntx subscale and the QLQ-CIPN20 autonomic subscale was poor (T2: r = - 0.354, p < 0.001; T3: r = 0.286, p < 0.001). Based on the MCID derived using distribution-based method, the MCID for the QLQ-CIPN20 sensory subscale was 2.5-5.9 (6.9% to 16.4% of the subdomain score) and for motor subscale was 2.6-5.0 (8.1%-15.6% of the subdomain score).

CONCLUSION

The MCID for the EORTC QLQ-CIPN20 established using distribution-based approaches was 2.5-5.9 for the sensory subscale and 2.6-5.0 for the motor subscale. When noted in assessments even with small change in scores, clinicians can be alerted for appropriate intervention.

摘要

背景/目的:这是第一项旨在确定欧洲癌症研究与治疗组织生活质量问卷-周围神经毒性 20 项量表(EORTC QLQ-CIPN20)的最小临床重要差异(MCID)的研究,该量表是一种经过验证的工具,旨在引出癌症患者对与化疗引起的周围神经病变相关的症状和功能限制的体验。

方法

接受神经毒性化疗的癌症患者在基线时(T1,n=287)、化疗第二周期(T2,n=287)和化疗后 12 个月(T3,n=191)完成 EORTC QLQ-CIPN20 和功能性评估癌症治疗/妇科肿瘤组-神经毒性(FACT/GOG-NTX)。基于锚定的方法使用经过验证的 FACT/GOG-NTX 神经毒性(Ntx)子量表来确定恶化的最佳 MCID 截止值。基于分布的方法使用 EORTC QLQ-CIPN20 总分的三分之一标准差(SD)、一半 SD 和一个标准测量误差。

结果

Ntx 子量表的变化分数与 QLQ-CIPN20 的感觉和运动子量表之间存在中度相关性(T2:r=-0.722,p<0.001 和 r=-0.518,p<0.001;T3:r=-0.699;p<0.001 和 r=-0.523,p<0.001,分别;T3:r=-0.699;p<0.001 和 r=-0.523,p<0.001,分别)。Ntx 子量表的变化分数与 QLQ-CIPN20 的自主子量表之间的相关性较差(T2:r=-0.354,p<0.001;T3:r=-0.286,p<0.001)。基于基于分布的方法得出的 MCID,QLQ-CIPN20 感觉子量表的 MCID 为 2.5-5.9(子域评分的 6.9%-16.4%),运动子量表的 MCID 为 2.6-5.0(子域评分的 8.1%-15.6%)。

结论

使用基于分布的方法确定的 EORTC QLQ-CIPN20 的 MCID 为感觉子量表的 2.5-5.9,运动子量表的 2.6-5.0。当注意到评分甚至有很小的变化时,临床医生可以提醒进行适当的干预。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验